331
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
Condition(s):Acute Lymphoblastic Leukemia; Large B-cell LymphomaLast Updated:March 8, 2021Recruiting
Relapsed Refractory Diffuse Large B Cell Lymphoma: 346 Clinical Trials, Page 34 of 35
Hide Studies Not Open or Pending
332
Oblimersen, Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin’s Lymphoma
Condition(s):Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell LymphomaLast Updated:January 24, 2013Completed
333
Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma
Condition(s):B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma; Central Nervous System Lymphoma; Intraocular Lymphoma; Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System; Recurrent Adult Diffuse Large Cell Lymphoma; Retinal LymphomaLast Updated:July 22, 2019Completed
334
Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma
Condition(s):LymphomaLast Updated:June 19, 2013Completed
335
Rituximab and Interleukin-2 in Treating Patients With Relapsed or Refractory Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
Condition(s):LymphomaLast Updated:July 18, 2013Completed
336
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma
Condition(s):Lymphoma, Non-HodgkinLast Updated:April 1, 2021Recruiting
337
Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin’s Lymphomas
Condition(s):Relapsed Chronic Lymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Diffuse Large B Cell Lymphoma; Follicular Lymphoma; Richter’s TransformationLast Updated:November 27, 2020Recruiting
338
Phase I/II Carfilzomib Plus Lenalidomide and Rituximab in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
Condition(s):LymphomaLast Updated:October 22, 2019Terminated
339
Mitoxantrone and Clofarabine for Treatment of Recurrent NHL or Acute Leukemia
Condition(s):Acute Lymphoblastic Leukemia; Acute Myelogenous Leukemia; Lymphoblastic Lymphoma; Diffuse Large B-cell Lymphoma; Burkitt Lymphoma/LeukemiaLast Updated:March 13, 2019Unknown status
340
Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia
Condition(s):Waldenstrom Macroglobulinemia; Multiple Myeloma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma; Lymphoplasmacytic Lymphoma; Marginal Zone Lymphoma; Mantle Cell Lymphoma; Diffuse Large B Cell LymphomaLast Updated:February 1, 2021Recruiting